Trial Profile
Clinical trial of tocilizumab for skin fibrosis in systemic sclerosis (Ver. Osaka)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 May 2019
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 01 May 2019 Status changed from active, no longer recruiting to discontinued.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2014 New trial record